Oral Abstract Session 1
Wednesday, September 4, 2024 09:15 AM - 10:15 AM
F3
Oral Abstracts
Chair:
Roberto Gramignoli, PhD, Gaslini Hospital, Italy
Included Abstracts:
Roberto Gramignoli, PhD, Gaslini Hospital, Italy
Included Abstracts:
- Gabriel Siracusano, PhD, Universita Vita Salute San Raffaele, Diabetes Research Institute (DRI), IRCCS San Raffaele Scientific Institute, Italy - Knock-out of the NK activating ligands in MHC-I-null human stem cell-derived β cells avoids chronic allogeneic rejection and reverts hyperglycemia in diabetic humanized mice
- Paul Dyer, PhD, Halo Labs Ltd, United Kingdom - Determination of contaminating particles in cell therapy products; a proof of principle study.
- Sylvain Perruche, PhD, MED'INN'PHARMA, France - Cell●Secret●Service Platform Transforms Secretomes from Resolution-associated Macrophages into Biological Drugs to be Evaluated in Therapy Refractory Scleroderma and Rheumatoid Arthritis
- Ibon Garitaonandia, PhD, MBA, CellProthera SAS, France - Development of an autologous CD34+ cell based therapy for the treatment of post-acute myocardial infarction
- Alex du Rand, BSc(hons), The University of Auckland, New Zealand - Developing an ex vivo CRISPR/Cas9 gene therapy for inherited skin disorders
- Marsel Khaliullin, BSc, Alabuga International School, Russian Federation - Special biotech zone: integrating whitehead’s process philosophy and industry 4.0 for workforce development
